Saltar al contenido
Merck
Todas las fotos(1)

Key Documents

View All Documentation

49963

Sigma-Aldrich

β-tri-Calcium phosphate

puriss. p.a., ≥98% β-phase basis (sintered Powder)

Sinónimos:

β-TCP, β-Tricalcium phosphate

Iniciar sesiónpara Ver la Fijación de precios por contrato y de la organización
Todas las fotos(1)

About This Item

Fórmula empírica (notación de Hill):
Ca3O8P2
Número de CAS:
7758-87-4
Peso molecular:
310.18
EC Number:
231-840-8
MDL number:
MFCD00015984
UNSPSC Code:
12352302
PubChem Substance ID:
329757549
NACRES:
NA.55

grade

puriss. p.a.

assay

≥98% β-phase basis (sintered Powder)

form

powder

impurities

≤50 mg/kg total heavy metals as lead
≤500 mg/kg total sulfur as SO4 (ICP)

anion traces

chloride (Cl-): ≤50 mg/kg

cation traces

As: ≤0.5 mg/kg
Ba: ≤20 mg/kg
Cd: ≤1 mg/kg
Co: ≤1 mg/kg
Cr: ≤10 mg/kg
Cu: ≤5 mg/kg
Hg: ≤0.5 mg/kg
Ni: ≤5 mg/kg
Pb: ≤5 mg/kg
Zn: ≤20 mg/kg

InChI

1S/3Ca.2H3O4P/c;;;2*1-5(2,3)4/h;;;2*(H3,1,2,3,4)/q3*+2;;/p-6

InChI key

QORWJWZARLRLPR-UHFFFAOYSA-H

¿Está buscando productos similares? Visita Guía de comparación de productos

Categorías relacionadas

Application


  • Tungstosilicic Acid: A Promising Electrolyte for Redox Flow Battery.: This study explores the use of tungstosilicic acid (TSA) as an electrolyte in redox flow batteries (RFB). The research highlights TSA′s high energy density due to its multi-electron transfer capability, making it a promising candidate for enhancing the efficiency and power density of RFBs. This advancement is particularly relevant for large-scale energy storage systems integrating renewable energy technologies (Sharma et al., 2023).

  • Heterogenization of a Tungstosilicic Acid Catalyst for Esterification of Bio-Oil Model Compound.: This paper explores the heterogenization of tungstosilicic acid by supporting it on silica-based materials for the esterification of bio-oil model compounds. The catalyst shows high activity and stability, indicating its potential for industrial applications in bio-oil upgrading (Prasertpong et al., 2022).


Analysis Note

Phase Composition (by XRD analysis):
ß-TCP: >98% ; Hydroxylapatite: <1.0% ; a-TCP: <0%; TTCP: 0%
other Ca-P phases as Calcium pyrophosphate <1.0%

Storage Class

11 - Combustible Solids

wgk_germany

WGK 1

flash_point_f

Not applicable

flash_point_c

Not applicable

Certificados de análisis (COA)

Busque Certificados de análisis (COA) introduciendo el número de lote del producto. Los números de lote se encuentran en la etiqueta del producto después de las palabras «Lot» o «Batch»

¿Ya tiene este producto?

Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.

Visite la Librería de documentos

Simon Storgård Jensen et al.
Clinical oral implants research, 17(3), 237-243 (2006-05-05)
The purpose was to qualitatively and quantitatively compare the bone formation and graft resorption of two different bone substitutes used in both orthopedic and oral surgery, with autogenous bone as a positive control. Three standardized bone defects were prepared in
S Yamada et al.
Biomaterials, 18(15), 1037-1041 (1997-08-01)
To study the influence of calcium phosphate ceramic solubility on osteoclastic resorption, neonatal rabbit bone cells were cultured for 2 days on hydroxyapatite (HA), beta-tricalcium phosphate (beta-TCP) and two types of biphasic calcium phosphate (BCP) with HA/beta-TCP ratios of 25/75
Crystal structure analysis of β-tricalcium phosphate Ca3(PO4)2 by neutron powder diffraction.
Yashima M, et al.
Journal of Solid State Chemistry, 175(2), 272-277 (2003)
Michael D Weiden et al.
PloS one, 9(10), e108476-e108476 (2014-10-02)
While exploring the effects of aerosol IFN-γ treatment in HIV-1/tuberculosis co-infected patients, we observed A to G mutations in HIV-1 envelope sequences derived from bronchoalveolar lavage (BAL) of aerosol IFN-γ-treated patients and induction of adenosine deaminase acting on RNA 1
C Lorenzo et al.
Cancer gene therapy, 22(11), 542-551 (2015-10-10)
Interleukin 12 (IL12) is a heterodimeric proinflammatory cytokine that has shown promise as an anticancer agent. However, despite encouraging results in animal models, clinical trials involving IL12 have been unsuccessful due to toxic side effects associated with its systemic administration
Ver todos los artículos relacionados

Nuestro equipo de científicos tiene experiencia en todas las áreas de investigación: Ciencias de la vida, Ciencia de los materiales, Síntesis química, Cromatografía, Analítica y muchas otras.

Póngase en contacto con el Servicio técnico